Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Team Grant: E-Rare Joint Transnational Call

McGill University

$224,436.00

PROSPAX: an integrated multimodal progression chart in spastic ataxias

EF 2019-20

Résumé
Spastic ataxias (SPAX) present an expanding group of >100 rare degenerative diseases with joined damage of cerebellum and corticospinal tract (CST). While rapid genetic stratification facilitates current development of molecular therapies, effective trial-planning for SPAX is hampered by a lack of valid outcome measures and natural history studies. Uniting all major European ataxia and spastic paraplegia networks, PROSPAX will establish a paradigmatic IRDiRC-guided integrated trial-ready model of disease progression and mechanistic evolution in SPAX, which will allow to track and understand selective as well as overlapping dysfunction of the cerebellum and CST. In a 2-year transatlantic natural history study we will validate clinician- and patient-reported, digital and molecular outcomes. In addition, PROSPAX will improve on existing and develop new outcome parameters that show superior sensitivity to change. These include a clinical SPAX composite score, a smartphone mHealth toolbox combining wearable sensors with app-based patient-entered outcomes, and multimodal MRI radiomics with an innovative machine learning approach for multisite MRI analysis. Single-cell multi-omic studies in mouse will identify shared pathways and vulnerabilities between cerebellar and corticospinal neurons and will unravel new molecular biomarkers. By example of the two most common recessive SPAX (SPG7, ARSACS) PROSPAX will create a paradigmatic trial-readiness pathway for charting disease progression and multimodal outcome measures that will be applicable to many of the >100 SPAX diseases alike.
Programme
Team Grant: E-Rare Joint Transnational Call
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
406801
Name
Brais Bernard
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
CNRS/INSERM (France); German Research Foundation (Germany); Fonds de recherche du Québec - Santé (FRQS); The French National Research Agency (France); The Netherlands Organization for Health Research and Development (ZonMw); Ministero della Salute (Italy); The Scientific and Technological Research Council of Turkey
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Special Cases
Projecttitle
PROSPAX: an integrated multimodal progression chart in spastic ataxias
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$224,436
Cihrequipment2
$0
Programname2
Team Grant: E-Rare Joint Transnational Call
Keyworddelim
Ataxia; Clinical Scales; Digital Biomarkers; Genetics; Molecular Biomarkers; Natural History; Neuromuscular Diseases; Proteomics; Registry; Transcriptomics
Abstract
Spastic ataxias (SPAX) present an expanding group of >100 rare degenerative diseases with joined damage of cerebellum and corticospinal tract (CST). While rapid genetic stratification facilitates current development of molecular therapies, effective trial-planning for SPAX is hampered by a lack of valid outcome measures and natural history studies. Uniting all major European ataxia and spastic paraplegia networks, PROSPAX will establish a paradigmatic IRDiRC-guided integrated trial-ready model of disease progression and mechanistic evolution in SPAX, which will allow to track and understand selective as well as overlapping dysfunction of the cerebellum and CST. In a 2-year transatlantic natural history study we will validate clinician- and patient-reported, digital and molecular outcomes. In addition, PROSPAX will improve on existing and develop new outcome parameters that show superior sensitivity to change. These include a clinical SPAX composite score, a smartphone mHealth toolbox combining wearable sensors with app-based patient-entered outcomes, and multimodal MRI radiomics with an innovative machine learning approach for multisite MRI analysis. Single-cell multi-omic studies in mouse will identify shared pathways and vulnerabilities between cerebellar and corticospinal neurons and will unravel new molecular biomarkers. By example of the two most common recessive SPAX (SPG7, ARSACS) PROSPAX will create a paradigmatic trial-readiness pathway for charting disease progression and multimodal outcome measures that will be applicable to many of the >100 SPAX diseases alike.
Competitiondate
201906
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Brais, Bernard
Approvedterm
3 ans 0 mois
Cihrcontribution2
Institute of Genetics~ $224,436~ $0~